Clinical Trial Update: Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC [Phase 2]

View source ↗

Summary

Phase 2 study update on adding duvelisib to docetaxel for recurrent/metastatic head and neck squamous cell carcinoma; the trial has completed and results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Duvelisib (duvelisib)

Snippet

Sponsor: Glenn J. Hanna | Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2025-03-05